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Cell-mediated immunity is a key weapon of host de-
fence against tuberculosis (TB). Granzyme A (GzmA), 
a serine protease, present in the granules of cytotoxic 
cells induces caspase-independent cell death. We esti-
mated the proportion of GzmA producing lymphocyte 
subsets in peripheral blood from 59 normal healthy 
volunteers and 48 pulmonary TB (PTB) patients using 
flow cytometry. When compared with normal healthy 
subjects, we observed a significantly higher percent-
age of GzmA-positive CD56+ cells (P = 0.01) in PTB 
patients. However, when the absolute number was 
compared between the two groups, a significantly de-
creased number of GzmA-expressing CD16+ (P = 0.01) 
and CD56+ (P = 0.0001) cells was observed in patients 
and this could be explained by the significantly re-
duced number of total lymphocytes (P = 0.0009) seen 
in the patients. There was no significant difference in 
the number of CD4+ and CD8+ GzmA double-positive 
cells between the two study groups. CD56 is a natural 
killer cell marker and these cells represent innate immune 
response to TB. We report an increased percentage of 
CD56+ cells expressing GzmA in TB patients, which 
shows the relevance of the GzmA-mediated pathway 
of apoptosis in immunity against Mycobacterium tuber-
culosis. 
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TUBERCULOSIS (TB) remains a serious global health 
threat despite effective treatment strategies. Mycobacte-
rium tuberculosis (MTB), an intracellular pathogen has 
the ability to persist in the host by successfully evading 
the defence mechanisms. A coordinated immune response 
involving innate and cell-mediated immunity is required 
to control the infection. Eradication of the pathogen requires 
lysis of the infected cells by cytotoxic T lymphocytes 
(CTL) and natural killer cells (NK cells). Recent studies 
with MTB-reactive CD8 T-cells have shown that cytolytic 
function was associated with inhibition of intracellular 
MTB growth1. The granule exocytosis pathway is an im-
portant mechanism by which the cytotoxic cells cause 
target cell lysis and death. The CTL granules contain a pore-
forming protein called perforin, and a group of serine 
proteases called granzymes in a proteoglycan matrix2. 
Granzymes enter the target cell with the help of perforin 
and accumulate in the nucleus, where they can activate 
pathways of nuclear damage3. Granzyme B causes caspase-
dependent cell death, whereas granzyme A (GzmA) me-
diates caspase-independent cell death4. 
 GzmA causes DNA damage by introducing single-
stranded nicks in the DNA5. It destroys the lamins and 
opens up the DNA for degradation by targeting the his-
tones6. GzmA causes irreversible damage to the target 
cell by cleaving the SET complex, which is involved in 
the repair response to oxidative stress7. Cells that are re-
sistant to caspase-mediated cell death are sensitive to the 
apoptotic effects of GzmA5. Studies have also shown that 
GzmA signals monocytes to have enhanced phagocytic 
activity and to produce elevated levels of IL-6, IL-8 and 
TNF-α, which suggests that granzymes may have important 
regulatory roles in cell mediated immunity8. 
 The aim of our study was to examine the proportions of 
peripheral blood lymphocyte subsets expressing GzmA in 
normal healthy subjects (NHS) and pulmonary tuberculosis 
(PTB) patients, which could reflect the in vivo situation in 
TB. 
 The study group included 48 PTB patients (mean 
age ± SD is 35.5 ± 10.6) and 59 NHS (mean age ± SD is 
30 ± 8). Patients attending Tuberculosis Research Centre 
(TRC), Chennai with respiratory symptoms and radio-
graphic abnormalities suggestive of PTB and sputum-
positive for MTB by both smear and culture were included 
for the study. All the patients were HIV-negative. Among 
the 48 patients, 32 were males (mean age ± SD is 35.8 ± 
11) and 16 females (mean age ± SD is 34.8 ± 10). NHS 
were volunteers who were clinically normal at the time of 
blood collection and the NHS group comprised 41 males 
(mean age ± SD is 31.3 ± 8.7) and 18 females (mean age ± 
SD is 25.8 ± 5). Blood samples were collected after ob-
taining informed consent and before starting chemother-
apy. The study has been approved by the ethical committee 
of TRC. 
 About 1 ml of blood was heparinized and used for in-
tracellular and surface-staining by flow cytometry and 
hematological profile using electron profile counter (ABX 
micros CE Haematalgie, France). Flow cytometric detection 
of intracellular GzmA in whole blood was performed 
based on a method described earlier9. Fluorescein isothio-
cyanate (FITC)-conjugated anti-CD4, CD8 and CD16 anti-
bodies and phycoerythrin (PE)-conjugated anti-CD56 
antibody (Becton Dickinson, California, USA) were used 
for surface-staining followed by lysis of red blood cells 
(RBC) with RBC lysis solution (Becton Dickinson). Leuco-
cytes were fixed in 1% para formaldehyde (PFA) for 10 min 
followed by permeabilization with 0.1% saponin in phos-
phate buffered saline (PBS). Intracellular staining was 
performed by incubating the cells with PE or FITC-
conjugated anti-GzmA antibody (Becton Dickinson) at 
4°C for 30 min. Stained cells were washed twice in PBS, 
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fixed with 1% PFA and acquired in Becton Dickinson 
FACSort flow cytometer. Using scatter pattern, 10,000 
events were counted in the lymphogated region and ana-
lysed using Cell Quest Pro software. Results were expressed 
as arithmetic mean ± standard error (SE) and analysed  
using Student’s t test to examine the significance of re-
sults between the two study groups. P value less than 
0.05 was considered statistically significant. 
 Dot-plot pictures showing scatter pattern of GzmA-
positive cells and their immunophenotypes from a NHS and 
a PTB patient are shown in Figure 1. The proportions of 
CD4+, CD8+, CD16+ and CD56+ cells expressing GzmA were 
compared between the study groups. When compared with 
NHS, there was a significant increase in the percentage of 
CD56+ GzmA-positive cells in PTB patients (P = 0.01). 
The percentage of CD4+ and CD8+ GzmA-positive cells 
was slightly higher in PTB patients, but the difference 
was not significant. In contrast, the percentage of CD16+ 
GzmA-positive cells was slightly decreased in PTB patients 
(Figure 2 a). 
 The absolute number of each subset was calculated 
from the total lymphocyte count. When we compared the 
absolute numbers between the two groups, a significantly 
decreased number of CD16+ (P = 0.01) and CD56+ 
(P = 0.0001) cell population, which stained positive for 
GzmA, was observed in PTB patients. This may be due to 
a significant reduction in the number of total lymphocytes 
(P = 0.0009) in PTB. There was no significant difference 
in the number of CD4+ and CD8+ GzmA double-positive 
cells between the two study groups (Figure 2 b). 
 Host defence against TB involves NK cells and CTLs. 
Recent studies have revealed that the CTLs deliver highly 
microbicidal proteins into infected macrophages, thereby 
killing the virulent pathogen, and lyse the target macro-
phages by granule-mediated perforin mechanism of apop-
tosis which co-delivers bactericidal proteins10. One such 
granule-associated protein is GzmA, which causes cell 
death by introducing single-stranded DNA nicks. Most 
circulating CD56+ NK cells, almost half of CD8+ T-cells 
and a few CD4+ T-cells express GzmA9. GzmA expres-
sion is constitutive in many NK cells and continues to be 
expressed long after T-cell activation11. 
 Considering these facts, we sought to study the expres-
sion of GzmA in lymphocyte subsets of peripheral blood 
from NHS and PTB patients. We observed a significantly 
increased percentage of GzmA-expressing CD56+ cells in 
PTB patients. The difference was not significant for other 
cell subsets. However, due to a general decrease in the 
number of lymphocytes in TB, the number of CD56+ 
GzmA-positive cells was low in the peripheral blood of 
patients. Such a decreased total lymphocyte number in 
PTB patients was reported in an earlier study from our 
laboratory, where we have shown an increased percentage 
of CD8+ cells positive for perforin in PTB patients12. A 
similar finding has been reported in a study by Carvalho 
et al., where they have observed that HIV-seronegative 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.
 Dot-plot pictures showing scatter pattern of peripheral 
blood cells with lymphogate and intracellular GzmA staining in CD4+, 
CD8+, CD16+ and CD56+ cells in NHS and PTB patients. PE–anti-
GzmA antibody was used with CD4, CD8 and CD16 staining and 
FITC–anti-GzmA antibody was used with CD56 staining. Numbers 
correspond to the percentage of gated cells in each quadrant and the re-
sults shown are representative data from an individual NHS and PTB 
patient sample. 
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Figure 2. a, Immunophenotypic classification of GzmA-positive cells 
in peripheral blood lymphocytes of NHS and PTB patients. The per-
centage of total lymphocytes, CD4+, CD8+, CD16+ and CD56+ cells 
positive for GzmA in NHS and PTB patients is shown. The percentage 
of CD56+ GzmA double-positive cells was significantly high in PTB 
patients (P = 0.01) when compared with NHS. b, Absolute numbers of 
GzmA-positive total lymphocytes, CD4+, CD8+, CD16+ and CD56+ 
cells in NHS and PTB patients. In PTB patients, there was a significant 
decrease in the absolute number of CD16+ GzmA double-positive cells 
(P = 0.01) and CD56+ GzmA double-positive cells (P = 0.0001). Re-
sults are expressed as mean ± SE. Figures in parentheses represent the 
number of subjects studied. 
 
TB patients had lower total lymphocyte and CD4+ propor-
tions than healthy blood donors13. However, the percentage 
of CD56+ cells positive for GzmA is significantly higher 
in these patients, which is a consequence of the infection. 
This may be because of the increased activation and pro-
liferation of these cells upon stimulation by the mycobac-
terial antigens. The surface-marker CD56 is present on 
NK cells, which mediate their action via cytolysis and 
production of Th1 cytokines. NK cells are also essential for 
the generation of human CD8+ allogenic CTL responses 
and this effect is mediated in part through CD56 (ref. 14). 
In the present study, an increased expression of GzmA in 
the CD56+ cells of PTB patients was observed. This could 
be due to an increased activation of these cytotoxic cells 
during infection or an increased production of GzmA in 
these cells in response to an external signal. GzmA 
causes apoptosis of target cells, a way to eliminate bacilli 
in the infected cells. In a study by Sada Ovalle et al., 
CD8 cells with the NK cell marker CD57 obtained from 
PTB patients had a high expression of intracellular per-
forin and GzmA15. These cells exhibited a significant 
spontaneous cytotoxic activity upon autologous monocytes 
in the absence of antigenic stimulus. Our study reports an 
increased percentage of GzmA-expressing NK cells in 
PTB patients, suggesting the relevance of GzmA-mediated 
apoptotic pathway in the defence against MTB. These re-
sults indicate an important role for GzmA in the host im-
mune response to TB, which needs to be confirmed with 
more functional studies. 
 To conclude, we report an increased percentage of 
GzmA-expressing CD56 cells in PTB, which supports the 
role played by these cytotoxic cells in the immune res-
ponse mounted against the pathogen. Functional studies 
about the role of GzmA in infectious diseases could provide 
more knowledge in this aspect. 
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